RxDoctor Payments Data

Ramiro Hernandez, MD

Neurology · Houston, TXNPI 1700135035

Payments from drug & device makers

$8,585in general payments, 2019–2025

Across 409 payments — averaging $20.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$1K
  • Novartis$772
  • SK Life Science, Inc.$680
  • AbbVie$544
  • Sunovion Pharmaceuticals Inc.$519
  • Biogen$400
  • plus $5K from 37 others

What the payments were for

  • Consulting fees$1502%
  • Speaking & faculty fees$1972%
  • Food & beverage$8,10294%
  • Education$1362%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,585 in reported general payments places this provider in the 65th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$17,296
Medicare patients
70
Services billed
177

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FirdapseAmifampridine Phosphate11$627,710
AptiomEslicarbazepine Acetate18$49,846
KeppraLevetiracetam15$35,645
RexultiBrexpiprazole20$32,494
Memantine Hcl ErMemantine Hcl104$6,977
Carbamazepine ErCarbamazepine32$2,793
Pyridostigmine Bromide20$2,238
Lacosamide15$1,910
Levetiracetam66$1,900
Memantine Hcl64$1,805
Donepezil Hcl123$1,060
Lamotrigine62$939
Oxcarbazepine13$819
Carbidopa-LevodopaCarbidopa/Levodopa29$731
Gabapentin84$686

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sunovion Pharmaceuticals Inc.Aptiom$519$49,84618 claims
Otsuka America Pharmaceutical, Inc.Rexulti$250$32,49420 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$161$2,23820 claims
Lilly USA, LLCOlanzapine$242$16712 claims
Upsher-smith Laboratories LLCTopiramate$65$13721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,246 neurology providers in Texas.

Other neurology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →